DB18231InvestigationalProtein Based Therapies
DF-1001: Overview.
- Also known as
- Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells
- Code names
- DF-1001
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of DF-1001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account